Latest News

Eli Lilly Offers Obesity Drug Directly to Consumers


 

Long-Term Picture

Research suggests the obesity medications must be taken continuously, at least for most people, to maintain the weight loss. In a study of patients on Zepbound, Dr. Aronne and colleagues found that withdrawing the medication led people to regain weight, while continuing it led to maintaining and even increasing the initial weight loss. While some may be able to use the medications only from time to time, “the majority will have to take these on a chronic basis,” Dr. Aronne said.

Obesity, like high blood pressure and other chronic conditions, needs continuous treatment, Dr. Apovian said. No one would suggest withdrawing blood pressure medications that stabilize blood pressure; the same should be true for the obesity drugs, she said.

Dr. Apovian consults for FORM, the telehealth platform Lilly uses for LillyDirect, and consults for Novo Nordisk, which makes Saxenda and Wegovy. Dr. Aronne is a consultant and investigator for Novo Nordisk, Eli Lilly, and other companies.

A version of this article appeared on WebMD.com.

Pages

Recommended Reading

Erectile Dysfunction Rx: Give It a Shot
MDedge Family Medicine
‘We Will Rock You’ Into Real-time Diabetes Control
MDedge Family Medicine
GLP-1 RAs Associated With Reduced Colorectal Cancer Risk in Patients With Type 2 Diabetes
MDedge Family Medicine
ED Visits for Diabetes on the Rise in the US
MDedge Family Medicine
Spending the Holidays With GLP-1 Receptor Agonists: 5 Things to Know
MDedge Family Medicine
FDA Issues Warning About Counterfeit Ozempic
MDedge Family Medicine
Walking Fast May Help Prevent Type 2 Diabetes
MDedge Family Medicine
Extreme Heat and Hypoglycemia Risk in Older Insulin Users
MDedge Family Medicine
Evidence Grows for SGLT2 Inhibitors in Rheumatology
MDedge Family Medicine
Are Post-Meal Insulin Surges Beneficial?
MDedge Family Medicine